Connect with us

Health

COVID-19 Vaccine: Nigeria to adopt “whole family” approach

Published

on

Share

The National Primary Health Care Development Agency (NPHCDA) has announced plans to adopt ”the whole family” approach in the second phase of the COVID-19 vaccination in order to integrate the exercise into other basic Primary Health Care (PHC) services

The exercise would cover PHC services like childhood vaccination, screening for hypertension, diabetes and malnutrition.

The Executive Director of NPHCDA, Dr Faisal Shuaib, disclosed this at a news conference on Tuesday in Abuja.

Shuaib said that this would ensure that while protecting eligible Nigerians against COVID-19, the agency also would be concerned about the total health of individuals and their entire family.

The executive director added that this would further enhance acceptability of the COVID-19 vaccine across the country.

“We are adopting ‘the whole family approach’ to integrate the COVID-19 vaccination with other basic PHC services such as childhood vaccination, screening for hypertension, diabetes, malnutrition.

“We will give residents another opportunity to listen to NPHCDA, State Primary Health Care Development Agency (SPHCDA) and the State Ministry of Health (SMoH) on how they can improve on personal hygiene, water and environmental sanitation.

”This is particularly important in view of the large number of cases of cholera that we are recording across the country,” he explained.

He disclosed that the agency had met with the Director General, National Agency for Food and Drug Administration and Control (NAFDAC), Dr Mojisola Adeyeye, to finalise discussion on how to continue the collaboration that led to effective vaccine monitoring and accountability experienced in the first phase of the COVID-19 roll out.

He added that this was effected using ‘track and trace’, an innovative approach first used in Nigeria during the first COVID-19 vaccination roll out.

He said that this was why first phase of the vaccination exercise was declared finished on July 9, as there was no available vaccines in the country, adding that ”this kind of accountability is what we want to replicate in the second phase rollout.

“This is as a result of the leadership provided by the Presidential Steering Committee (PSC), FMoH, NAFDAC, NCDC and of course the NPHCDA,” he said.

According to him, the reason why we had to extend/postpone the launch date of the vaccine is because we want to institute once again, in conjunction with NAFDAC, the track and trace all the way to health facility where the vaccines would be administered.

He explained that the agency was locally creating labels for the vaccines barcode that would ensure that the tracking and tracing continued like it did in the first phase.

Speaking on the brands of COVID-19 vaccines available in Nigeria, he said that as of Aug. 10, 2021, the country had received 4,000,080 doses of the Moderna COVID-19 vaccine, donated by Government of the United States of America.

He, however, said that the country was expecting additional vaccines between August and September 2021, including Oxford AstraZeneca, Johnson & Johnson, Moderna and Pfizer.

Shuaib stated that while the agency was hopeful and well-prepared to roll out the second phase vaccination plan, it was by no means oblivious of the fact that there were challenges ahead, especially now that the country had started receiving different brands of COVID-19 vaccines.

“We are aware that Nigerians would want to know if there is a preferred brand. Let me assure everyone that COVID-19 vaccines, regardless of brand, as long as they have been approved by NAFDAC, provide adequate protection against the disease.

“We want to further assure Nigerians that we have strategised with our partners so that there is no confusion on which vaccines will be given to whom.

“For example, all those who have taken their first dose of AstraZeneca vaccines and are due for their 2nd dose would be given their second dose in this month of August as we are expecting up to 588,800 doses of the AstraZeneca vaccine from the COVAX facility.

“This is the first batch that will be coming in the next couple of days, thereafter we will be expecting up to 3.9 million doses of the AstraZeneca vaccines to complement what we already have and to make sure we cover not only those who will be taking their second AstraZeneca vaccine but also for those who will want to take their 1st dose of this vaccine.

“In all communications, we have been clear that the AstraZeneca and Moderna vaccines are very effective against the Delta variant as cases are beginning to increase in states like Lagos and Akwa Ibom,” he explained.

Shuaib stressed that only person who is 18 years and above is eligible to receive Moderna or any other brand of COVID-19 vaccine available.

According to him, it is pertinent to state that mixing one brand of vaccine with another brand in first and second dose is not allowed.

“Those who have received AstraZeneca as first dose should receive AstraZeneca as second dose, while those who will receive Moderna as first dose will receive Moderna as second dose when due.

”In a few days, we will take delivery of additional AstraZeneca vaccine and those who are due for second dose of the vaccine will be prioritised.

“Most brands of COVID-19 vaccine require two doses of varying intervals between the doses for full protection. Moderna is two doses, four weeks apart; Oxford AstraZeneca is two doses with six to 12 weeks apart; and Pfizer is two doses, three weeks apart.

“However, brands such as Johnson and Johnson that we are receiving tomorrow (Wednesday) require a single dose for full protection against the virus.

“The initial dose that we will be receiving will be focused on those who are in the hard-to-reach areas (riverine areas, desert areas) and the elderly because they are people who may find it difficult to leave their homes to the health facility for a second dose vaccine,” he explained.

He said that settlements, houses of traditional rulers, markets, motor parks and other places where people congregate would be reached out in the second phase.

He therefore urged Nigerians to ensure they complete their doses for full protection.

“Consequently, we want to call on all Nigerians to remain assured that the vaccines that we have are safe and will be deployed next week as earlier communicated.

”The flag off and roll out of the second phase of the COVID-19 Vaccination programme will be done on August 16th, 2021,” he said.

According to him, government is currently wrapping up the training of about 40,739 health workers across the national, state and ward levels under phase 2 strategic vaccine roll out plan with focus on improving the delivery, communication, data management, management of the vaccines and logistics.

He however urged Nigerians who had taken the vaccines to speak to their loved ones, friends and colleagues, and encourage them to get vaccinated.

“Because for us to stop this pandemic, we need a critical herd immunity that can only be approached when we reach at least 70 per cent herd immunity.

“So, it is not just for the public health expert, but the responsibility of Nigerians who have taken the vaccines and have the right information to provide these information to their loved ones and community members to take the vaccine.

“Even as we increase the vaccination coverage across Nigeria, let us continue to observe the non-pharmaceutical measures such as wearing of facemask, physical distancing and hand hygiene,” he advised.

The country has received 4,000,080 doses of Moderna COVID-19 vaccine donated by the government of the United States, and will be receiving 176,000 doses of Johnson & Johnson vaccines on Aug. 11.

The 176,000 doses is coming out of the 29,850,000 doses the federal government procured from the AFREXIM Bank through the African Union. (NAN) 

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Health

Experts Seek Unified Action against Cervical Cancer

Published

on

Share

Torough David, Abuja

Stakeholders across health sectors have called for urgent, coordinated investment in prevention, equitable HPV vaccine access and harmonized health data to accelerate progress towards elimination of cervical cancer across Africa.

They made the call on Wednesday, during a panel session with the Theme ”Accelerating Cervical Cancer Elimination in Nigeria, From Policy to Practice”.

Head of Division, Maternal, Newborn, Child and Adolescent Health, Africa CDC, Dr Fidele Ngabo Gaga, highlighted its efforts to harmonise and aggregate health data across all 55 African Union (AU) Member States.

“We are developing a continent-wide data-sharing agreement and centralised repository to support data upstreaming and policy development.

“The goal is to present unified data at AU Summits, helping countries make evidence-based decisions,” Gaga said:

Prof. Imran Morhason-Bello, a leading gynaecologic oncologist from the University College Hospital, Ibadan, made a compelling financial case for prioritising prevention over treatment.

“Screening just between 2023 and 2027 will cost Nigeria N351 billion.

“But treating 10,000 women with invasive cervical cancer from 2027 to 2030 could cost us N1.4 trillion. Prevention is not only more humane, it is far more cost-effective,” he said.

Morhason-Bello also addressed innovations such as self-sampling for HPV testing, already being implemented in Nigeria through implementation science.

“Women receive a self-sampling kit, return it the same day, and positive results are treated before noon.

“It is happening in markets and schools. It is not a pilot, it is real.

“We have even developed a mobile app (available in multiple languages and offline) to guide women through the self-sampling process, increasing accessibility in low-resource settings,” he said.

External Affairs Director for MSD, Sub-Saharan Africa, Vuyo Mjekula, addressed one of the most common myths around the HPV vaccine rollout.

“Let me be clear, there is no shortage of HPV vaccines. If anyone tells you otherwise, call me directly. The real issue is equity and strategic allocation,” she said.

Mjekula recalled early proposals that included boys in HPV vaccination efforts, but warned that without careful planning, some countries would be left out entirely.

She called for one national policy that ensures equitable access to vaccines and services, especially for the most vulnerable girls.

“This is not about science alone. A dose costing N125,000 may be affordable to some, but to a woman in a rural village, it is like N10 million.

“If she must choose between survival and feeding her children, the answer is obvious,” she said.

She applauded Nigeria’s progress, noting that since the national rollout, the number of vaccinated girls across the continent has more than doubled, driven primarily by Nigeria’s leadership.

Mjekula also made an appeal for multi-sectoral collaboration, urging the involvement of private sector giants, from banks to telecoms and philanthropic foundations.

“Health is not just the government’s responsibility. We need to imagine beyond the healthcare we can afford with public funds and work toward the healthcare we want as a society,” she said.

She also called for a business case for investment in HPV prevention and cancer control, saying the task force must work hand-in-hand with all stakeholders.

“Let us go far together. If you want to go quickly, go alone. But if you want to go far, go together,” she said.

The symposium concluded with a call to integrate cancer screening into primary health care services.

It also called for the deployment of cost-effective technologies like self-sampling, addressing myths around vaccine shortages, and ensuring gender-sensitive, data-informed policies.

As Nigeria and the continent advance towards achieving the WHO 90-70-90 cervical cancer elimination targets, the message from experts was clear: “Let us do big and let us do it together”.

Continue Reading

Health

89% of Infants Vaccinated Globally in 2024, WHO, UNICEF Warn of Risks

Published

on

Share

The United Nations agencies have reported that in 2024, approximately 89 per cent of infants worldwide, about 115 million children, received at least one dose of the diphtheria, tetanus, and pertussis (DTP) vaccine.This update comes from new national immunisation coverage data released on July 14 by the World Health Organisation (WHO) and the United Nations Children’s Fund (UNICEF).

Compared to 2023, an additional 171,000 children received at least one vaccine dose, and one million more completed the full three-dose DTP series.
While these gains are modest, they reflect ongoing global efforts to protect children in spite of rising challenges.However, nearly 20 million infants still missed at least one DTP vaccine dose in 2024, including 14.
3 million “zero-dose” children who never received any vaccine.This figure exceeds the 2024 target by four million, putting global immunisation goals outlined in the Immunisation Agenda 2030 at risk.WHO Director-General Dr Tedros Ghebreyesus emphasised the life-saving power of vaccines, stating, “It’s encouraging to see an increase in children vaccinated, but we still have much work to do. “Cuts in aid and vaccine misinformation threaten to reverse decades of progress.”He highlighted factors contributing to under-vaccination, including limited healthcare access, supply disruptions, conflict, and misinformation.“Data from 195 countries show 131 have consistently reached at least 90 per cent coverage with the first DTP dose since 2019. Yet, progress is stalling in 47 countries, with 22 nations seeing declines after previously meeting this target.”Tedros warned that conflict and humanitarian crises significantly undermined vaccination efforts.“A quarter of the world’s infants live in 26 fragile or conflict-affected countries, which account for half of all unvaccinated children globally.“In these areas, unvaccinated children rose from 3.6 million in 2019 to 5.4 million in 2024, highlighting an urgent need for integrated immunisation in humanitarian responses.“Immunisation coverage in 57 low-income countries supported by Gavi, the Vaccine Alliance, improved in 2024, reducing the number of under-vaccinated children by about 650,000.“Yet, some upper-middle- and high-income countries face early signs of declining coverage, which increases the risk of disease outbreaks.”UNICEF Executive Director Catherine Russell welcomed the progress but warned millions of children remained vulnerable to preventable diseases.She called for urgent action to overcome barriers such as shrinking health budgets, fragile systems, misinformation, and conflict-related access issues.Russell noted encouraging expansions in vaccines against HPV, meningitis, pneumococcal disease, polio, and rotavirus.“Global HPV vaccine coverage among eligible adolescent girls rose from 17 per cent in 2019 to 31 per cent in 2024, although it remains far below the 90 per cent target set for 2030.”Gavi CEO Dr Sania Nishtar added that while lower-income countries protected more children than ever, population growth, fragility, and conflict continued to hamper equity in vaccination efforts.She highlighted improvements in measles coverage but cautioned that it still fell short of the 95 per cent threshold required to prevent outbreaks.“Measles outbreaks nearly doubled from 33 countries in 2022 to 60 in 2024.”Nishtar stressed that funding shortfalls, instability, and rising misinformation threaten to stall or reverse progress, risking increased deaths from vaccine-preventable diseases.WHO and UNICEF called on governments and partners to close funding gaps for Gavi’s 2026–2030 strategic cycle to protect millions of children.They also urged strengthening immunisation efforts in conflict-affected and fragile settings, and prioritising locally led strategies and increased domestic investment in primary healthcare systems.Additionally, the agencies emphasised the need to counter vaccine misinformation through evidence-based campaigns.They also called for greater investment in robust data collection and disease surveillance systems to guide effective immunisation programmes. (NAN)

Continue Reading

Health

Nigeria Records 145 Lassa Fever Deaths, as Fatality Rate Increases

Published

on

Share

Nigeria has recorded 145 deaths from Lassa fever as of 2025 Epidemiological Week 25, with a case fatality rate (CFR) of 18.6 percent.

The Nigeria Centre for Disease Control and Prevention (NCDC), disclosed this in its latest report via its official website during the weekend in Abuja.

The NCDC said the week 25 figure marks an increase from 17.

6 percent reported for the same period in 2024.

The report, which covered the week of June 16–22, revealed that 781 confirmed cases were reported out of 5,943 suspected cases across 20 states and 101 Local Government Areas (LGAs).

In the current reporting week, 10 new confirmed cases were reported in Ondo and Edo states with a slight increase from the eight cases recorded the previous week.

According to NCDC, 91 per cent of all confirmed cases in 2025 were reported from five states of Ondo (31%), Bauchi (24%), Edo (17%), Taraba (16%) and Ebonyi (3%).

It said that the disease continues to affect young adults predominantly, within the 21 to 30 age group most impacted. Males were slightly more affected, with a male-to-female ratio of 1:0.8.

The Nigerian public health agency, said that despite a decline in the overall number of suspected and confirmed cases compared to 2024, the rise in CFR is raising concerns among health experts.

The agency highlighted late presentation of cases, high treatment costs, and poor health-seeking behaviour as contributing factors to the increased fatality.

It said that no new infections among health workers were recorded in the reporting week, though 23 healthcare workers have been affected cumulatively this year.

The NCDC said it is currently in collaboration with partners, such as the World Health Organisation (WHO), the United States Centers for Disease Control and Prevention (US CDC), ALIMA, the Institute of Human Virology Nigeria (IHVN) and others.

The collaborations, it stated further, have intensified multi-sectoral response efforts to combat the spread of Lassa fever.

It said that, as part of these efforts, Integrate clinical trials are currently ongoing in Ondo State, with After Action Reviews (AARs) conducted in both Ondo and Ebonyi to evaluate the response to the outbreak.

The agency said that clinician sensitisation, community engagement activities and environmental response campaigns have been carried out in identified hotspot areas.

In addition, the NCDC said that it has deployed 10 national rapid response teams to various states, adopting a one health approach to disease control.

To further strengthen infection prevention and control (IPC), the agency launched an IPC e-learning platform and distributed updated Viral Hemorrhagic Fever (VHF) guidelines to health facilities across the country.

The agency said that other efforts also included active contact tracing, surveillance, media engagement and geospatial risk mapping, alongside regular webinars for clinicians and capacity-building sessions nationwide.

The NCDC identified key challenges including poor environmental sanitation and low community awareness, particularly in high-burden LGAs.

It also said that sustained efforts were needed to curb the fatality rate, ensure early detection, and improve public health outcomes.

The NCDC advised Nigerians to maintain proper hygiene, avoid contact with rodents, and seek medical help promptly when experiencing symptoms such as fever, sore throat, vomiting, or unexplained bleeding.

Lassa fever, which was first identified in 1969 in Lassa, Borno, is endemic in Nigeria, with outbreaks occurring annually.

Symptoms range from mild fever and joint pain to severe bleeding from the nose, mouth, and gastrointestinal tract.

The disease is fatal in about 20 percent of cases, particularly when treatment is delayed.

Across West Africa, hundreds of thousands are infected annually, experiencing symptoms such as fever, vomiting and, in severe cases, bleeding.

One of the most troubling complications is hearing loss, which affects about 25 percent of survivors.

The estimated fatality rate is one per cent, but during outbreaks, mortality can rise significantly, particularly among pregnant women and healthcare workers.

In spite of its significant health impact, Lassa fever remains one of the most neglected diseases, with limited resources allocated to its preventions and treatments.

Currently, no licensed vaccines exist, although around 20 candidates are in development, with the most advanced in Phase IIa clinical trials.

Continue Reading

Read Our ePaper

Top Stories

POLITICS1 day ago

Anambra: INEC Registers 96,085 New Voters, Extends CVR by Three Days

ShareThe Independent National Electoral Commission (INEC) said it has registered 96,085 new voters in nine days and extended the exercise...

NEWS1 day ago

Tinubu Honors Buhari, Renames University of Maiduguri after Late President

ShareBy David Torough, Abuja President Bola Tinubu has approved the renaming of the University of Maiduguri, Borno State as Muhammadu...

NEWS1 day ago

C’River First Female NUJ Chairman Describes Tenure as Trial Period

ShareThe first female Chairman of the Nigeria Union of Journalists (NUJ) in Cross River, Archibong Bassey has said that her...

NEWS1 day ago

Gov Makinde Confered With Prestigious Chieftaincy Title of Aare Omoluabi of Akure Land by Akure Kingdom

ShareThe Akure Kingdom will today bestow a prestigious chieftaincy title, Aare Omoluabi of Akure Land, meaning President of the Respectable...

POLITICS1 day ago

PDP Stakeholders Olorunda Pass Vote of Confidence on Gov Adeleke

ShareFrom Ayinde Akintade, Osogbo The Olorunda Peoples’ Democratic Party, PDP, Stakeholders has passed vote of confidence on Governor Ademola Adeleke...

NEWS2 days ago

Town Planners Task Benue Govt on Regional Devt, Master Plans

ShareBy David Torough, Abuja The President, Nigerian Institute of Town Planners (NITP), Dr. Chime Ogbonna, has urged the Benue State...

NEWS2 days ago

Illegal Detention: Court Awards Bauchi Accountant General N100m

ShareBy David Torough, Abuja In a decisive rebuke of official impunity, the Federal High Court sitting in Bauchi has declared...

NEWS2 days ago

Military Cracks Down on Terror Collaborators, Exposes Arms Trafficking by Transport Union Members

ShareBy David Torough, Abuja The Defence Headquarters (DHQ) has announced multiple breakthroughs in its ongoing counter-terrorism operations, revealing that Nigerian...

NEWS2 days ago

Peace, Order Return to Niger LG after Series of Banditry Attacks

ShareFrom Dan Amasingha, Minna Rijau Local Government Area, one of the Frontline Councils under sustained banditry attack is now heaving...

NEWS2 days ago

LG Pensions/Gratuities: Bayelsa Warns Principal Officers Against Sabotage of Quick Payment Policy

ShareFrom Mike Tayese, Yenagoa Bayelsa State Government has warned principal officers of local government councils in the state to desist...

Copyright © 2021 Daily Asset Limited | Powered by ObajeSoft Inc